Cardiomyopathies
2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis
24 Jan, 2023 | 14:29h | UTCKey Points: 2023 ACC Expert Consensus on Cardiac Amyloidosis – American College of Cardiology
Commentary on Twitter
.@ACCinTouch's 🆕 Expert Consensus Decision Pathway provides practical and timely guidance on the diagnosis and management of cardiac #amyloidosis, with an emphasis on comprehensive multidisciplinary care.
Learn more: https://t.co/1SunbtuQpO#JACC #CardioOnc #CardioTwitter pic.twitter.com/DLvFUpajHC
— JACC Journals (@JACCJournals) January 23, 2023
The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies
9 Jan, 2023 | 14:10h | UTC
Commentary on Twitter
The Year in Cardiovascular Medicine 2022 series: the Top 10 papers in Heart Failure and Cardiomyopathies https://t.co/w6opcMPcBa@escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes #HeartFailure #Cardiomyopathies pic.twitter.com/UrrX2LUQdI
— European Society of Cardiology Journals (@ESC_Journals) January 2, 2023
Cohort Study | Prognostic prediction of genotype vs. phenotype in genetic cardiomyopathies.
23 Nov, 2022 | 13:57h | UTC
Commentary on Twitter
We are out with our last big work on the importance of genotype for the prognostic stratification of Cardiomyopathies! @CardiologyASUGI @Trieste_Denver @JACCJournals @PaldinoAlessia https://t.co/82byVNnUhK pic.twitter.com/KYoxDXkzr6
— matteo dal ferro (@matteodalferro) November 17, 2022
Under a Creative Commons license
Review | Differing strategies for sudden death prevention in hypertrophic cardiomyopathy.
4 Nov, 2022 | 13:28h | UTCDiffering strategies for sudden death prevention in hypertrophic cardiomyopathy – Heart
Consensus Paper | Diagnosis and management of syncope in hypertrophic cardiomyopathy.
31 Oct, 2022 | 13:49h | UTC
Cohort Study | Highly malignant disease in childhood-onset arrhythmogenic right ventricular cardiomyopathy.
24 Oct, 2022 | 14:08h | UTCEditorial: Arrhythmogenic cardiomyopathies in children: seek and you shall find – European Heart Journal
Commentary on Twitter
Highly malignant disease in childhood-onset arrhythmogenic right ventricular cardiomyopathy: discover more in EHJ!https://t.co/kA60A1zjRt#ARVC #children #screening #heart #transplantation #cardiotwitter @escardio @ESC_Journals pic.twitter.com/fq4X8doBMI
— EHJ Editor-in-Chief (@ehj_ed) September 6, 2022
Under a https://creativecommons.org/licenses/by-nc/4.0/ License
Review | Restrictive cardiomyopathy: definition and diagnosis.
24 Oct, 2022 | 13:58h | UTCRestrictive cardiomyopathy: definition and diagnosis – European Heart Journal
Commentary on Twitter
⚠️Great review 👉 Restrictive cardiomyopathy
📍definition
📍diagnosis
📍therapies available only for cardiac amyloidosis and, for iron overload cardiomyopath🆓📁 https://t.co/OtO7L45SBw pic.twitter.com/L55mPnmNtt
— Alfonso Valle (@ValleAlfonso) October 22, 2022
Under a https://creativecommons.org/licenses/by-nc/4.0/ License
Review | Cardiac care of children with Duchenne muscular dystrophy (DMD) and females carrying DMD-gene variations.
20 Oct, 2022 | 12:21h | UTCCardiac care of children with dystrophinopathy and females carrying DMD-gene variations – openheart
Incidence of myocarditis/pericarditis following mRNA COVID-19 vaccination among children and younger adults in the US.
13 Oct, 2022 | 13:51h | UTC
Commentary on Twitter (thread – click for more)
Let me me perfectly clear about the evidence for myocarditis after mRNA vaccines
1. There is a notable increased incidence, age 12-39, males, with each dose (Table)https://t.co/XXQbyeLiSP pic.twitter.com/wLTZT3fppy— Eric Topol (@EricTopol) October 12, 2022
Commentary on Twitter
Let me me perfectly clear about the evidence for myocarditis after mRNA vaccines
1. There is a notable increased incidence, age 12-39, males, with each dose (Table)https://t.co/XXQbyeLiSP pic.twitter.com/wLTZT3fppy— Eric Topol (@EricTopol) October 12, 2022
Guideline | Evaluation and management of myocarditis.
12 Oct, 2022 | 13:56h | UTC
Cohort Study | Cardiovascular MRI phenotypes and long-term outcomes in patients with suspected cardiac sarcoidosis.
30 Sep, 2022 | 12:39h | UTCCardiovascular Magnetic Resonance Imaging Phenotypes and Long-term Outcomes in Patients With Suspected Cardiac Sarcoidosis – JAMA Cardiology (link to abstract – $ for full-text)
Commentary on Twitter
Cardiovascular magnetic resonance phenotypes could be used to optimize clinical decision-making for treatment options, such as implantable cardioverter-defibrillators, and thus improve outcomes in patients with suspected cardiac #sarcoidosis. https://t.co/6hlpPFd7cd #Research
— JAMA Cardiology (@JAMACardio) September 14, 2022
Clinical risk score to predict pathogenic genotypes in patients with dilated cardiomyopathy.
26 Sep, 2022 | 11:57h | UTC
Commentary on Twitter
Is it possible to predict which pts w/ dilated cardiomyopathy/left ventricular dysfunction will have an assoc. predisposition on genetic testing?
Via the Madrid Score, Drs. @LuisEscobarL, @dr_pavia, & colleagues work to answer this question in #JACC: https://t.co/WDn8jA29aY pic.twitter.com/u0T9FffOwi
— JACC Journals (@JACCJournals) September 13, 2022
Retrospective Cohort Study | Natural history of MYH7-related dilated cardiomyopathy.
14 Sep, 2022 | 13:06h | UTC
20-year follow-up of a RCT trial | Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy.
26 Jul, 2022 | 13:33h | UTCCommentary: Immunosuppression may benefit long term in virus-negative inflammatory cardiomyopathy – Healio (free registration required)
Commentary on Twitter
Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial@escardio @ESC_Journals #CardioTwitter #EHJhttps://t.co/XpZj0UrJo5 pic.twitter.com/PIq0Bzwhpu
— EHJ Editor-in-Chief (@ehj_ed) July 19, 2022
Under a https://creativecommons.org/licenses/by/4.0/ license
RCT | Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.
13 Jul, 2022 | 11:52h | UTC
RCT | First-line catheter ablation of monomorphic ventricular tachycardia in cardiomyopathy concurrent with defibrillator implantation.
11 Jul, 2022 | 12:21h | UTC
Commentary on Twitter
#OriginalResearch: In #PAUSE_SCD RCT, early first-line catheter ablation performed concurrent with ICD implantation for monomorphic VT significantly reduced the composite primary outcome of VT recurrence, CV hospitalization, or death @DrRoderickTung https://t.co/ifQvG9A4j5 pic.twitter.com/5WAcPz3Mlm
— Circulation (@CircAHA) May 5, 2022
Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy.
8 Jul, 2022 | 11:53h | UTCRelated:
AHA Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis.
Case Series | Myocardial injury in patients with acute and subacute Chagas Disease in the Brazilian Amazon using cardiovascular magnetic resonance.
5 Jul, 2022 | 11:47h | UTCArrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator.
5 Jul, 2022 | 11:29h | UTCEditorial: Arrhythmogenic right ventricular cardiomyopathy: the never-ending quest for a risk calculator
Cohort Study | Novel risk prediction model to determine adverse heart failure outcomes in arrhythmogenic right ventricular cardiomyopathy.
4 Jul, 2022 | 11:53h | UTCEditorial: Predicting Heart Failure in Arrhythmogenic Right Ventricular Cardiomyopathy
Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside.
29 Jun, 2022 | 11:01h | UTCPharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside – Drugs
Brief Review | Never above suspicion: getting to the bottom of cardiac sarcoidosis diagnosis and treatment.
29 Jun, 2022 | 10:50h | UTC
Indications and utility of cardiac genetic testing in athletes.
28 Jun, 2022 | 11:03h | UTC
Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada.
27 Jun, 2022 | 11:51h | UTCCommentary: Young Men’s Myocarditis Risk 5 Times Higher With Moderna vs Pfizer Vax — But Canadian study finds that 8-week interval before second dose attenuates some of the risk – MedPage Today (free registration required)
Cohort Study: Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA.
22 Jun, 2022 | 12:07h | UTCCommentaries:
COVID-19 mRNA vaccination and myocarditis or pericarditis – The Lancet
Myocarditis and Pericarditis After the COVID-19 mRNA Vaccination – American College of Cardiology
Related:
Myocarditis following a third Pfizer vaccination dose in military recruits in Israel.
Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong.
Myocarditis after BNT162b2 vaccination in Israeli adolescents.
[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.
Heart-inflammation risk from Pfizer COVID vaccine is very low.